Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03110380 · ClinicalTrials.gov registry record · Phase 3
Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Adults Who Are Virologically Suppressed
A Phase 3 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 567
- Enrollment target
NCT03110380 is a Phase 3 study that has completed, run by Gilead Sciences. The registered enrollment target is 567 participants.
The verdict
NCT03110380, a Phase 3 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 567 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the efficacy of switching from a regimen of either dolutegravir (DTG) and emtricitabine /tenofovir alafenamide (F/TAF) or DTG and emtricitabine/tenofovir disoproxil fumarate (F/TDF) to a fixed dose combination (FDC) of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus DTG+F/TAF in virologically suppressed HIV-1 infected adults with or without antiretroviral (ARV) resistance.
Interventions
- DRUG B/F/TAF
- DRUG F/TAF
- DRUG F/TAF Placebo
- DRUG DTG
- DRUG DTG Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 567 participants |
| Start Date | 2017-06-12 |
| Est. Completion | 2021-02-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03110380
The ClinicalTrials.gov registry entry for NCT03110380 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 567 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which B/F/TAF is the first listed.
NCT03110380 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03110380 about?
NCT03110380 is a clinical study titled "Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Adults Who Are Virologically Suppressed". The primary objective of this study is to evaluate the efficacy of switching from a regimen of either dolutegravir (DTG) and emtricitabine /tenofovir alafenamide (F/TAF) or DTG and emtricitabine/tenofovir disoproxil fumarate (F/TDF) to a fixed dose combination (FDC) of bictegravir/emtricitabine/teno...
What is the current status of trial NCT03110380?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 567 participants. The study started on 2017-06-12. Estimated completion is 2021-02-10.
What interventions are being tested in trial NCT03110380?
The interventions under investigation include: B/F/TAF (DRUG), F/TAF (DRUG), F/TAF Placebo (DRUG), DTG (DRUG), DTG Placebo (DRUG).
Who is sponsoring clinical trial NCT03110380?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.